Valirx (VAL)

 

VAL Share PerformanceMore

52 week high17.2999 16/05/16
52 week low3.6750 23/02/17
52 week change -10.5000 (-73.68%)
4 week volume9,759,477 29/01/17

Media for (VAL)

Presenter: Suzanne Dilly
01/12/2016
Presenter: Suzanne Dilly
02/11/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ValiRx notes positive VAL201 clinical trial

ValiRx announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety a...

CLINICAL TRIAL UPDATE - Positive VAL201 Results

RNS Number: 8311T ValiRx PLC 11 January 2017 y Va li R x P lc ("ValiRx" or "the Company") CLINICAL TRIAL UPDATE 'Positive VAL201 Results' London, UK ., 11 January 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety and to...

ValiRx notes Yorkville CLN conversion

ValiRx said YA Global Master SPV Ltd (Yorkville) has elected to convert a further portion of tranche 1 of the Convertible...

Yorkville CLN Conversion

RNS Number: 0006T ValiRx PLC 30 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Yorkville CLN Conversion London, UK ., 29 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards comm...

ValiRx says European patent granted for VAL201

ValiRx said a patent (Anti-Androgen Peptides and Uses Thereof in Cancer Therapy) covering its lead therapeutic compoun...

European Patent Granted for Lead Compound VAL201

RNS Number: 2297R ValiRx PLC 08 December 2016 Va li R x P lc ("ValiRx" or "the Company") EUROPEAN PATENT GRANTED FOR LEAD THERAPEUTIC COMPOUND VAL201 London, UK ., 08 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel techn...

ValiRx loan draw down

ValiRx has drawn down the second tranche of its convertible loan facility with YA Global Master SPV Ltd for the amoun...

Convertible Loan Facility

RNS Number: 8716Q ValiRx PLC 02 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK ., 02 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commerci...

Fundamental DataMore

EPS-6.66
Dividend yield0 %

Equity Research (VAL)

edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Re: possible 5p placing

    Yes you may well be right. All will be revealed in time. When I retired from work in my mid 50's I decided that having made a reasonable amount of money following small cap ...
    24-Feb-2017
    Tired and Confused
  • Re: possible 5p placing

    In my opinion only. Get out with whatever you can get while you can.
    23-Feb-2017
    Sabrage
  • Re: possible 5p placing

    Could be anything from bad news leaking out regarding drugs to just rumour. One thing is for sure, once a share like this gets downward momentum it tends to fall quickly. ...
    23-Feb-2017
    Tired and Confused

Users' HoldingsMore

Users who hold Valirx also hold..
ROCKHOPPER18%
SOUND ENERGY18%
RANGE RES.17%
LLOYDS GRP.16%
SAREUM16%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL